OPY:NYSEOppenheimer Holdings, Inc. Analysis
Data as of 2026-04-22 - not real-time
$118.02
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Oppenheimer Holdings is trading at $118.02, comfortably above the 20‑day ($101.23), 50‑day ($92.34) and 200‑day ($77.58) moving averages, confirming a strong bullish bias. Technical momentum is reinforced by a bullish MACD crossover (line $7.66 above signal $6.21) and a price near the recent resistance of $118.77, while an RSI of 84.7 flags the stock as overbought in the short run.
Fundamentally, the stock appears dramatically undervalued: a trailing P/E of 9.1 versus the industry average of 17.6, a price‑to‑book of 1.26, and a DCF‑derived fair value of $481.37 suggest a large upside potential. Revenue is expanding at a robust 27.8% with a 91% gross margin and 35% operating margin, and the balance sheet is net‑cash positive (cash $1.45B vs debt $1.23B). The dividend yield of 0.63% is supported by a modest 5.5% payout ratio, indicating sustainability. Despite the high leverage ratio (debt‑to‑equity 123%), the company’s strong cash generation and low payout provide a cushion, though forward earnings appear compressed, inflating the forward P/E to 46.1. The stock’s 30‑day volatility of ~30% and beta around 1.07 signal moderate market sensitivity, while stable volume and a market cap of $1.26B mitigate liquidity concerns.
Fundamentally, the stock appears dramatically undervalued: a trailing P/E of 9.1 versus the industry average of 17.6, a price‑to‑book of 1.26, and a DCF‑derived fair value of $481.37 suggest a large upside potential. Revenue is expanding at a robust 27.8% with a 91% gross margin and 35% operating margin, and the balance sheet is net‑cash positive (cash $1.45B vs debt $1.23B). The dividend yield of 0.63% is supported by a modest 5.5% payout ratio, indicating sustainability. Despite the high leverage ratio (debt‑to‑equity 123%), the company’s strong cash generation and low payout provide a cushion, though forward earnings appear compressed, inflating the forward P/E to 46.1. The stock’s 30‑day volatility of ~30% and beta around 1.07 signal moderate market sensitivity, while stable volume and a market cap of $1.26B mitigate liquidity concerns.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI indicating overbought conditions
- Price approaching short‑term resistance
- Bullish MACD and trend still intact
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation gap (low P/E vs industry, DCF upside)
- Strong revenue growth and high margins
- Net‑cash position and sustainable dividend
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Durable cash generation and low payout ratio
- Undervalued relative to peers with upside potential
- Exposure to capital‑markets franchise with growth opportunities
Key Metrics & Analysis
Financial Health
Revenue Growth27.80%
Profit Margin9.56%
P/E Ratio9.1
ROE16.02%
ROA4.17%
Debt/Equity123.26
P/B Ratio1.3
Op. Cash Flow$188.8M
Industry P/E17.6
Technical Analysis
TrendBullish
RSI84.7
Support$83.60
Resistance$118.77
MA 20$101.23
MA 50$92.34
MA 200$77.58
MACDBullish
VolumeStable
Fear & Greed Index86.98
Valuation
Fair Value$481.37
GradeUndervalued
TypeBlend
Dividend Yield0.63%
Risk Assessment
Beta1.07
Volatility29.67%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.